Quick Summary — 5-Amino-1MQ
- What it is: A small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase) — an enzyme that throttles your body’s fat-burning capacity by depleting NAD+ precursors.
- Mechanism: Blocks NNMT in adipose tissue, which restores cellular methylation balance, raises NAD+ availability, and removes the metabolic governor that’s been keeping your fat cells “sleepy.”
- Who it’s for: Stubborn-fat lifters, women in perimenopause, anyone over 35 watching metabolic rate decline despite training hard.
- Differentiator vs alternatives: Doesn’t stimulate the central nervous system like ephedrine or clen. Doesn’t manipulate hormones. Removes a metabolic brake instead of slamming the gas pedal.
- Natural Plus angle: This is a perfect example of Law 1 — Governors vs Accelerators. Stop trying to push harder. Take the parking brake off first.
What 5-Amino-1MQ Actually Does (At The Molecular Level)
5-Amino-1-methylquinolinium (5-Amino-1MQ) is one of the most interesting compounds to come out of metabolic research in the last decade, and almost nobody outside specialist circles is talking about it correctly. It is a selective, small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase, abbreviated NNMT.
NNMT does something specific and consequential. It takes nicotinamide (a precursor to NAD+) and methylates it using a methyl group donated from S-adenosylmethionine (SAM), producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH) as byproducts. In adipose tissue, NNMT activity is dramatically elevated in obesity, in metabolic dysfunction, and as a function of aging. The result is a double hit on metabolism: nicotinamide gets diverted away from NAD+ synthesis (lowering cellular energy charge), and SAM gets depleted (impairing methylation reactions across the cell, including in DNA and histones).
5-Amino-1MQ inhibits NNMT with high selectivity. When NNMT is blocked, nicotinamide is preserved for NAD+ synthesis, SAM is preserved for proper methylation, and the entire energetic and epigenetic state of the adipocyte shifts toward a more youthful, metabolically active phenotype. The 2018 Neelakantan et al. study showed that NNMT inhibition in obese mice produced significant fat loss without changing food intake — the metabolic brake came off, and stored fat began to be utilized.
5-Amino-1MQ is orally bioavailable. Half-life is approximately 4-6 hours in humans (still under characterization). It is highly selective for NNMT and does not significantly inhibit other methyltransferases or off-target enzymes at therapeutic concentrations. It does not stimulate the central nervous system, does not raise heart rate or blood pressure, and does not interact with hormonal systems — which is exactly what makes it different from every other “fat burner” on the market.
The Tony Huge Laws of Biochemistry Physics — Law 1 in Action
This is the cleanest illustration I can give you of Law 1 of the Tony Huge Laws of Biochemistry Physics — Governors vs Accelerators. Every biological system has both. Most people only push the accelerators. Real optimization means simultaneously removing governors AND pushing accelerators.
For decades, fat loss strategy has been all accelerator. Stimulants (caffeine, ephedrine, clenbuterol) push thyroid and adrenergic systems. Thermogenics force more substrate burning. Higher cardio volume drives more energy expenditure. All accelerator pedal, no thought to the governors that are increasingly active as we age.
NNMT is one of those governors. It’s a metabolic brake that gets stronger with obesity, age, and chronic inflammation. Pushing the gas harder while the brake is engaged is exactly the parking-brake analogy from Law 1 — you can floor the accelerator but you won’t move fast until you release the brake. This is why so many people in their 40s and beyond find that “the same things that worked at 30 don’t work anymore.” It’s not that the accelerator broke. It’s that the governors got stronger and nobody addressed them.
5-Amino-1MQ targets the governor directly. You stop fighting your own metabolism and let normal energy expenditure resume. Combined with appropriate accelerators (training, modest caloric deficit), the results are disproportionate to the pushing effort.
Natural Plus Protocol — How I Actually Run It
This compound is newer in the underground space than peptides like BPC-157, so dosing protocols are still evolving. This is the protocol that maps closely to the published mouse-to-human translation:
- Dose range: 100-150 mg per day, divided into 2 doses (morning and afternoon). Some sources push 150-200 mg/day. I see no evidence the higher dose meaningfully increases efficacy.
- Cycle length: 8-12 weeks on, then 4 weeks off. The off-cycle gives you a chance to assess what gains are stuck and what was just water/glycogen shift.
- Timing: Morning dose 30 minutes before breakfast. Afternoon dose 6-8 hours later. This maintains coverage through the day during the period when you’re metabolically active.
- Stack consideration: Pair with NMN or NR (nicotinamide riboside) — counterintuitive but logical. NNMT inhibition preserves the nicotinamide you have, but adding NAD+ precursors fills the pool further. The combination produces noticeably better results than either alone.
- Diet: Don’t use this as an excuse to eat poorly. The mechanism is releasing a brake on fat utilization — there still has to be a moderate caloric deficit for fat to move. I run it during a 200-400 calorie/day deficit, not aggressive crash dieting.
- What to monitor: Bodyweight and body composition (DEXA or caliper) at week 0, 4, 8, 12. Fasting glucose. Lipid panel. Some users report improved lipid profile during use, which is consistent with the metabolic mechanism.
Stacking Recommendations — Receptor Diversification
| Stack Compound | Pathway | Why It Synergizes |
|---|---|---|
| NMN or NR | NAD+ precursor | Floods the NAD+ pool that 5-Amino-1MQ stops being depleted. Direct synergy on the same metabolic axis from opposite directions. |
| Tesamorelin | GHRH analog (visceral fat target) | Targets visceral adipose specifically while 5-Amino-1MQ targets adipocyte metabolic rate generally. Independent mechanisms, additive results on body fat. |
| Berberine | AMPK activation | AMPK-mediated improvements in glucose disposal and insulin sensitivity reinforce the metabolic environment 5-Amino-1MQ creates. |
| Cardarine (low-dose, short cycle) | PPAR-delta | PPAR-delta drives fatty acid oxidation in muscle. NNMT inhibition releases fatty acid availability from adipose. Supply meets demand. |
Who Actually Benefits From 5-Amino-1MQ
- Lifters with stubborn fat — particularly that last 5-10 lbs that won’t move despite a perfect diet and training program. The brake-release mechanism specifically targets the metabolically resistant fat depots.
- Women in perimenopause — declining estrogen accelerates NNMT activity in adipose tissue, which is part of why the same diet that worked at 35 stops working at 45. NNMT inhibition is mechanistically appropriate for this population.
- Anyone over 35-40 watching their metabolic rate decline despite consistent training. The decline is partly NNMT-driven.
- Lifters with low energy on a deficit — preserving NAD+ during caloric restriction means cellular energy production stays online instead of crashing as it normally does on a cut.
- Post-bariatric or post-significant-weight-loss patients — NNMT remains elevated for years after weight loss, contributing to regain risk. Inhibition may help maintain the new set point.
It is NOT for: anyone hoping for crash weight loss, those who won’t combine it with diet discipline, anyone with severe liver dysfunction, or pregnant or nursing women.
Realistic Timeline — What To Expect
| Timeframe | What To Expect |
|---|---|
| Week 1-2 | Subtle changes. Possibly mild energy lift. Some users report better sleep within the first week. No dramatic body composition shift yet. |
| Week 4 | Body composition shift becoming visible — particularly in the trunk and lower abdomen. Improved energy on caloric deficit. Better metabolic flexibility (less crashes when meals are delayed). |
| Week 8 | Clear fat loss progress, often in areas that previously stalled. Total losses typically 4-8 lbs of fat depending on baseline and adherence. |
| Week 12 | Maximum benefit window. Time to cycle off and assess. Most fat losses retained if diet stays controlled — the underlying metabolic shift partially persists. |
Interesting Perspectives — What Most Articles Miss
The NNMT story rewrites the obesity narrative. For decades, the framework has been “calories in, calories out, mostly behavior.” NNMT research suggests that adipose tissue in obese individuals is actively metabolically suppressed by enzymatic activity that gets worse with obesity itself — a self-reinforcing biological loop. This isn’t an excuse for behavior. It’s a mechanistic explanation for why behavior alone often isn’t enough, particularly at the margins. NNMT inhibition is the first compound class to cleanly target this loop.
Cross-domain longevity relevance. NAD+ depletion is one of the central themes of biological aging. NNMT activity contributes to that depletion in adipose tissue specifically. Compounds that lower NNMT activity — whether 5-Amino-1MQ pharmacologically or exercise and methionine restriction biologically — are anti-aging interventions in addition to fat-loss interventions. This puts 5-Amino-1MQ in the same conversation as rapamycin and metformin for healthspan, not just bodybuilding.
Contrarian take: The supplement industry has spent 30 years selling stimulant-based “fat burners” that work for 4-6 weeks before tachyphylaxis kicks in and your central nervous system tells you to stop. 5-Amino-1MQ works on a completely different timescale and mechanism. The industry is structurally not set up to sell something that requires patient compliance over 8-12 weeks rather than producing an immediate dopamine hit from a stim. The compound that actually works is at odds with the marketing model. This is not unique to 5-Amino-1MQ — it’s the same reason peptides took so long to penetrate the consumer market.
Pattern recognition from underground use: Users who stack 5-Amino-1MQ with NMN and pair with strength training (not just cardio) report the most dramatic body composition changes. The cardio-only crowd sees less dramatic shifts because the demand for fatty acid oxidation isn’t as high as in resistance-trained populations. Train heavy, supply the fuel mechanism.
Emerging research angle: NNMT is now being investigated as a therapeutic target for non-alcoholic fatty liver disease (NAFLD), insulin resistance, and even certain cancers (where NNMT is upregulated and contributes to tumor metabolism). 5-Amino-1MQ is the prototype molecule, but expect a wave of NNMT inhibitors with optimized pharmacokinetics in the next 5 years.
FAQ
What is 5-Amino-1MQ?
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) — an enzyme that suppresses adipose metabolism by depleting NAD+ precursors. Inhibiting NNMT releases a metabolic brake on fat-burning.
What’s the right 5-Amino-1MQ dose?
100-150 mg per day, split into a morning and afternoon dose. Cycles run 8-12 weeks on, 4 weeks off. Higher doses don’t appear to increase efficacy meaningfully.
Are there side effects from 5-Amino-1MQ?
Side effect profile is exceptionally clean compared to traditional fat-loss compounds. No CNS stimulation, no heart rate elevation, no hormonal disruption. Mild GI upset is occasionally reported. Long-term human safety data is still developing.
Can 5-Amino-1MQ stack with peptides?
Yes, and the most synergistic stack combines 5-Amino-1MQ with NMN (NAD+ precursor) and Tesamorelin (visceral fat). Different mechanisms targeting the same outcome from different angles.
Who should use 5-Amino-1MQ?
Lifters with stubborn fat, women in perimenopause, anyone over 35 with declining metabolic rate, and people coming off significant weight loss who want to maintain results. Not for those expecting crash weight loss without diet adherence.
References
- Neelakantan H, et al. “Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.” Biochemical Pharmacology, 2018. DOI: 10.1016/j.bcp.2018.01.040
- Kraus D, et al. “Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.” Nature, 2014. DOI: 10.1038/nature13198
- Pissios P. “Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme.” Trends in Endocrinology & Metabolism, 2017. DOI: 10.1016/j.tem.2017.02.004
- Neelakantan H, et al. “Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase.” Journal of Medicinal Chemistry, 2017. DOI: 10.1021/acs.jmedchem.7b00389
- Hong S, et al. “Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization.” Nature Medicine, 2015. DOI: 10.1038/nm.3882
Related Articles
- Spermidine + Rapamycin: the autophagy-mtor longevity stack
- Tesamorelin: the fda-approved ghrh for Visceral Fat
- Adipotide: The Fat-Cell-Killing Peptide Big Pharma Abandoned
- Anti-Aging Peptides that actually work: Science Update
- TRT and peds after 40: Complete Guide for Fathers and Older Men